1146955-35-2

Usage

Uses

Used in Medicinal Chemistry:
2-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole is used as a building block for the synthesis of potential drug candidates due to its complex structure and potential biological activities.
Used in Pharmaceutical Research:
In pharmaceutical research, 2-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole is used for exploring its pharmacological activities, which include anti-inflammatory, anti-cancer, and anti-microbial properties.
Used in Organic Synthesis:
The boron-containing group in 2-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole allows it to be used in Suzuki-Miyaura coupling reactions, making it a valuable tool for organic synthesis and the development of new chemical compounds.
Used in Research and Development:
Due to its potential for pharmacological activities and its utility in organic synthesis, 2-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole is an important target for further research and development in the field of medicinal chemistry.

Upstream product

• 87-60-5 3-chloro-2-methylbenzenamine 
• 186407-74-9 4-bromoindazole 
• 110-87-2 3,4-dihydro-2H-pyran 
• 1266386-31-5 4-bromo-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole 
• 73183-34-3 bis(pinacol)diborane 
• 41748-71-4 4-aminoindazole 
• 603-83-8 3-nitro-o-tolylamine 
• 2942-40-7 nitro-4 indazole 
• 885618-33-7 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole 
• 1137278-45-5 4-chloro-1-(tetrahydro-2H-pyran-2-yl)-2H-indazole 
• 1146955-34-1 4-chloro-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole 
• 13096-96-3 4-chloro-1H-indazole 

Downstream Products

• 1391926-36-5 C₂₈H₃₁N₇O₄ 
• 1391926-60-5 C₃₁H₃₀N₆O₅S 
• 1391926-39-8 C₂₉H₃₃N₇O₄ 
• 1391926-34-3 4-(4-(benzylthio)-6-(2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-4-yl)-1,3,5-triazin-2-yl)morpholine 
• 1391926-38-7 C₃₁H₃₀N₆O₃S 
• 1391926-45-6 C₂₇H₃₀N₆O₃ 
• 1391925-55-5 3-((4-(1H-indazol-4-yl)-6-morpholino-1,3,5-triazin-2-yl)amino)-N,N-dimethylbenzamide 
• 1542268-06-3 (1r,4r)-4-((4-(2H-indazol-4-yl)-6-morpholino-1,3,5-triazine-2-yl)oxy)-N,N-dimethycyclohexanecarboxamide hydrochloride 
• 1542268-07-4 C₂₈H₃₇N₇O₄ 

Relevant academic research and scientific papers

Discovery of Novel and Orally Bioavailable Inhibitors of PI3 Kinase Based on Indazole Substituted Morpholino-Triazines

A new class of potent PI3Kα inhibitors is identified based on aryl substituted morpholino-triazine scaffold. The identified compounds showed not only a high level of enzymatic and cellular potency in nanomolar range but also high oral bioavailability. The three lead molecules (based on their in vitro potency) when evaluated further for in vitro metabolic stability as well as pharmacokinetic profile led to the identification of 26, as a candidate for further development. The IC50 and EC50 value of 26 is 60 and 500 nM, respectively, for PI3Kα enzyme inhibitory activity and ovarian cancer (A2780) cell line. The identified lead also showed a high level of microsomal stability and minimal inhibition activity for CYP3A4, CYP2C19, and CYP2D6 at 10 μM concentrations. The lead compound 26, demonstrated excellent oral bioavailability with an AUC of 5.2 μM at a dose of 3 mpk in mice and found to be well tolerated in mice when dosed at 30 mpk BID for 5 days.

NOVEL TRIAZINE COMPOUNDS

The present invention relates to novel triazine compounds of formula (1). The present invention also discloses compounds of formula I along with other pharmaceutical ac-ceptable excipients and use of the compounds to modulate the PI3K/ mTOR pathway

A practical synthesis of a PI3K inhibitor under noncryogenic conditions via functionalization of a lithium triarylmagnesiate intermediate

We report a practical synthesis of PI3K inhibitor GDC-0941. The synthesis was achieved using a convergent approach starting from a thienopyrimidine intermediate through a sequence of formylation and reductive amination followed by Suzuki-Miyaura cross-coupling. Metalation of the thienopyrimidine intermediate involving the intermediacy of triarylmagnesiates allowed formylation under noncryogenic conditions to produce the corresponding aldehyde. We also investigated aminoalkylation via a benzotriazolyl-piperazine substrate as an alternative to the reductive amination route. We evaluated both palladium and nickel catalyzed processes for the borylation and Suzuki-Miyaura cross-coupling. Final deprotection and salt formation afforded the API.

NOVEL TRIAZINE COMPOUNDS

The present invention relates to novel triazine compounds of formula (1), methods of their preparation, pharmaceutical compositions containing these compounds and the use of these compounds to treat proliferative disorders such as tumors and cancers and also other conditions and disorders related to or associated with dysregulation of PI3 Kinases, PI3 Kinase pathway, mTOR and/ or the mTOR pathway.

METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND

The present invention relates to a method for manufacturing a boronic acid ester compound, characterized by reacting an aryl halide compound and a diboron ester compound in the presence of a nitrogen-containing organic base, a nickel catalyst, a phosphine compound and a solvent. According to the manufacturing method of the present invention, even if a nickel catalyst is used as the catalyst, a desired boronic acid ester compound can be obtained in a sufficiently high yield. Furthermore, even if aryl chloride or aryl bromide having relatively low price and low reactivity, was used as the aryl halide compound, a desired boronic acid ester compound can be obtained in a sufficiently high yield.

METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND

The present invention relates to a method for manufacturing a boronic acid ester compound, characterized by reacting an aryl halide compound and a diboron ester compound in the presence of a nitrogen-containing organic base, a nickel catalyst, a phosphine compound and a solvent. According to the manufacturing method of the present invention, even if a nickel catalyst is used as the catalyst, a desired boronic acid ester compound can be obtained in a sufficiently high yield. Furthermore, even if aryl chloride or aryl bromide having relatively low price and low reactivity, was used as the aryl halide compound, a desired boronic acid ester compound can be obtained in a sufficiently high yield.